Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Chinese medicine pad pasting for preventing and controlling myopic eye, eyestrain symptoms and eyebase ischemia

A technology for visual fatigue and myopia, applied in sensory diseases, drug combinations, pharmaceutical formulations, etc., can solve problems such as damage to the inner eye tissue, difficult to treat the back tissue of the eye, and unsuitable for long-term application.

Inactive Publication Date: 2008-10-08
北京华恒汉方制药有限公司 +4
View PDF0 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, eyedrops or eye ointment on the surface of the eye are difficult to treat the diseases of the back of the eye. At the same time, only a small part of the drug (5%-10%) enters the cornea, sclera, and conjunctiva to be absorbed, while most of the drugs pass through the nasolacrimal duct. The system, nasal mucosa, and gastric mucosa are absorbed into the systemic circulation, and some may even cause systemic toxic and side effects
Subconjunctival injection, intravitreal injection, and retrobulbar injection of drugs may damage intraocular tissues, which require certain technical operations and are not suitable for long-term application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0113] Example 1: Wang Junbo, male, 14 years old, a student of No. 48 middle school in this city. Private prosecution: binocular vision decreased for one year, no glasses. The visual acuity of both eyes was 0.25 in the initial examination, and the refractive examination: right -1.25D ball, left -1.00D ball. After wearing the eye bags for a week, the visual acuity of the right eye was 1.2, and the visual acuity of the left eye was 1.0. After the treatment, the visual acuity of both eyes was the same as before.

example 2

[0114] Example 2: Wang Ying, female, 14 years old, a middle school student, has been short-sighted for half a year and has never had glasses. The visual acuity of both eyes at the first visit was 0.5, and the near vision was 1.2. The refractive index was randomly checked. The right eye: -200D ball, the left eye -2.50D ball. 1.0, one month after continued treatment, the visual acuity of both eyes was 1.5.

[0115] Schedule:

[0116] Name

[0117] Right: 0.8

[0118] Right: 0.1

[0119] Right: 0.4

[0120] Right: 0.25

[0121] Data three

[0122] Department of Ophthalmology, Affiliated Hospital of Anhui University of Traditional Chinese Medicine

[0123] 1. 93 cases of nasal diseases were treated with eye and nose traditional Chinese medicine bags, including 42 males and 51 females, aged 3-61 years.

[0124] There were 31 cases of atrophic rhinitis, 31 cases of chronic rhinitis and sinu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Short sight, visual fatigue and ischemic ophthalmopathy belong to the cataract diseases of oculopathy and are mostly caused by emotion problems or body fluid loss, blood shortage, weak kidney and liver which lead to the disorder of entrails, no moistening of eyes, blood stasis, etc., thus causing the loss of sight and even other neopathy. The treatment principle is that the traditional Chinese medicine components which can strengthen the liver and the kidney, supplement blood and body fluid, activate blood circulation to dissipate blood stasis, invigorate the spleen, and be beneficial for moistening are selected; the medicinal materials are extracted (63 percent of effective components, 30 percent of film-forming agent and 7 percent of plasticizer) and blended evenly to make the Chinese medicinal plaster with the thickness of 0.08 to 0.12cm and the plaster is then dried at the normal temperature (the temperature is controlled below 40 DEG C), cut and packaged into a finished product. The medicine can be applied to the skin around the eye and be finally acted on the target area in the ocular fundus after being absorbed by capillary vessels of the skin into the blood circulation of the eye.

Description

technical field [0001] The invention relates to a traditional Chinese medicine sticking film for preventing and treating myopia, visual fatigue and fundus ischemic eye disease and a process preparation method of the sticking film. technical background [0002] Human beings live in a bright world, and more than 80% of the information entering the brain is received by the eyes. Myopia's distant vision impairment and shortened visual distance not only restrict people from doing a lot of work, but also affect the introduction of more information from the outside world, which brings a lot of inconvenience to normal life. Even more frightening is the complication fundus degeneration, which seriously affects visual function and is one of the main causes of blindness in young adults. According to the statistics of the American Academy of Ophthalmology in 1989, 1 / 4 of the world's 4 billion population has 1 billion people suffering from myopia, and Asians, especially Chinese, have a ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/815A61K36/884A61K36/8905A61K9/70A61K47/32A61P27/10A61K31/045
Inventor 魏文斌韦企平郑志强马德林
Owner 北京华恒汉方制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products